Vanda Pharmaceuticals heads into its May 6 Q1 results carrying the heaviest short interest build of the past two months — and a history of double-digit post-earnings drops that will keep every positioning decision charged this week.
The short interest story has moved fast. SI climbed 71% over the past month to 9.8% of the free float, with roughly half that jump arriving in the two weeks after April 10. The week alone added 10%, bringing estimated short shares to 5.82 million — the highest reading in the 30-day window tracked. Days to cover of 5.45 (per the most recent FINRA fortnightly) amplify the tightness: unwinding the position is not a one-day exercise. Borrowing costs remain comparatively modest at 0.58% annualised, ticking up 22% over the month but not yet signalling a hard-to-borrow squeeze. Availability is also loose — the lending pool is nowhere near exhausted at current utilisation of just 4% — meaning new short demand can be met without material friction for now. The overall picture is a short position that has grown quickly and deliberately, without yet hitting the borrow constraints that typically precede a squeeze.
Options positioning tells a quieter story. The put/call ratio is 0.11, barely above its 20-day average of 0.10 and well below the kind of defensive readings that would suggest hedging panic into earnings. With a z-score of 0.8, options are roughly in line with recent norms. Bulls dominate the options book, and the 52-week low PCR of 0.05 shows just how call-heavy this market has been over the past year. That call skew sits in clear contrast to the short-side build — one camp is paying for upside, another is paying for downside via the share-borrow market.
The Street is broadly constructive, but the targets reflect a wide range of conviction. Four analysts carry Buy ratings, and the consensus return potential exceeds 120% at a mean target of $15.50 versus a $7.00 close. Truist Securities initiated coverage in early March with an $18 Buy, joining HC Wainwright — which raised its target to $24 — as the most bullish voices. Jefferies, however, holds a Hold with a $7.50 target, essentially marking the stock at fair value right where it trades. The bear case centres on generic competition for iloperidone eating into cash flows, with Bysanti needing to deliver to fill the gap. The bull case rests on tradipitant's commercial potential, particularly for GLP-1 RA-induced nausea — a market with real scale if the regulatory path clears. Analyst coverage data is dated to early March, so no fresh Street moves are recorded ahead of this print.
The insider register is worth noting. A coordinated cluster of sells landed on March 2 — the CEO, CFO, CMO, General Counsel, and an SVP all sold in a single session, totalling roughly $2.6 million collectively. The CEO, Mihael Polymeropoulos, sold 156,235 shares at $8.17. Net of those sales, 90-day insider activity shows a net buyer position of 344,342 shares worth $2.8 million — reflecting earlier purchases by Polymeropoulos in mid-2025 at prices well below current levels (around $4.15-$4.40). The recent sell cluster at $8+ stands out as insiders who bought near $4 taking partial profits above their cost basis.
Earnings history adds urgency to the setup. The last print (February 2026) produced an 18% drop on day one, followed by a further 1% decline over five days. A nearly identical pattern appeared across multiple readings of that same event — a consistent signal that the stock punished sellers of good news or disappointed holders materially. Prior to that, reactions in the same ballpark have been the norm. The short-side build of 71% over a month, arriving directly ahead of May 6, frames the next print less as a debate about pipeline progress and more as a test of whether longs — who still own a call-heavy options book — absorb or capitulate on any negative headline.
What to watch: whether the borrow pool tightens materially in the two trading sessions before May 6, and whether the options PCR shifts toward puts in the final 24 hours — both would suggest the short-side thesis is attracting momentum, not just structural positioning.
See the live data behind this article on ORTEX.
Open VNDA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
